Eli Lilly and Company

Ligand Pharmaceuticals, Inc.

Lourdes Prieto

James Allen Monn

Carlos Montero Salgado

Lorena Taboada Martinez

Alan M Warshawsky

David Edward Tupper

Robert J Ardecky

Stephen Richard Baker

Barry P Clark

Dawn Alisa Brooks

Carlos Lamas-Peteira

Jose Alfredo Martin

Christopher David Beadle

Rafael Ferritto Crespo

Isabel Rojo

Maria Rosario Gonzales Garcia

Bruce William Shaw

Alicia Torrado

Maria Martin-Ortega Finger

Teresa Tse Ki Man

Lesley Walton

Chahrzad Montrose-Rafezadeh

Anne-Reifel Miller

The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.

Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist

The present invention provides certain tetrahydrotriazolopyridine derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same. Formula (I) wherein Ris hydrogen, fluoro, chloro, or methyl; and Ris C4-CS branched alkyl. 

Tetrahydrotriazolopyridine compounds as selective MGLU5 receptor potentiators useful for the treatment of schizophrenia

The present invention provides novel mGlu2/3 agonists of the formula wherein R, R, and Rare as defined herein, for use in the treatment of neurological or psychiatric disorders.

MGlu 2/3 agonists

The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.

MGLU2 agonists

Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, &#x2014;CH&#x2014; or &#x2014;CHCH&#x2014;; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to Rand W, Ris (CH)&#x2014;CH(OR)&#x2014;(CH)E, &#x2014;(CH)&#x2550;C(OR)&#x2014;(CH)E, &#x2014;(CH)&#x2014;CH(Y)&#x2014;(CH)E or (CH)&#x2550;C(Y)&#x2014;(CH)E; wherein E is COOR, C&#x2013;Calkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C&#x2013;Calkyl, haloalkyl and aryl-C-4-alkyl; Ris H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, &#x2014;COR, &#x2014;COOR, &#x2014;CONRR, &#x2014;C(S)R, &#x2014;C(S)ORor C(S)NRR, Ris H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O&#x2014;, CH&#x2014;, &#x2014;CHCH&#x2014; or CH&#x2550;CH&#x2014; and is bonded to a carbon atom in Phenyl Ring A that is ortho to R. R&#x2013;Rare independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2 

Modulators of peroxisome proliferator activated receptors

Growing community of inventors

Madrid, Spain

Lourdes Prieto